<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610657</url>
  </required_header>
  <id_info>
    <org_study_id>AG348-C-024</org_study_id>
    <nct_id>NCT05610657</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Pharmacokinetic Study of Mitapivat in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agios Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agios Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the pharmacokinetics (PK) of a single oral&#xD;
      dose of mitapivat in participants with moderate hepatic impairment to that in matched healthy&#xD;
      control participants with normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 (Predose) to Extrapolated to Infinity Time (AUC∞) of Mitapivat</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Mitapivat</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Mitapivat</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (tmax) of Mitapivat</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of Mitapivat</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Clearance (CL/F) of Mitapivat</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Mitapivat</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction Unbound (fu) for Mitapivat in Plasma</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), AEs by Severity, and Relatedness to Study Treatment</measure>
    <time_frame>Up to Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Laboratory Evaluations, Based on Coagulation, Hematology, Clinical Chemistry and Urinalysis Test Results</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in 12-lead Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Vital Sign Measurements</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Physical Examination Findings</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Moderate Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mitapivat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitapivat tablet as a single oral dose, under fasted conditions on Day 1 to compare participants with normal hepatic function to participants with moderate hepatic function (Child-Pugh [C-P] Score B, score of 7 to 9).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitapivat</intervention_name>
    <description>Mitapivat tablets</description>
    <arm_group_label>Mitapivat</arm_group_label>
    <other_name>AG-348</other_name>
    <other_name>AG-348 sulfate hydrate</other_name>
    <other_name>Mitapivat sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all Participants-&#xD;
&#xD;
          -  Age: between 18 and 65 years of age;&#xD;
&#xD;
          -  Men and women of any race;&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0 and 34.0 kilograms per square meter (kg/m^2),&#xD;
             inclusive with at least 50 kg of body weight;&#xD;
&#xD;
          -  There should be no use of tobacco- or nicotine-containing products within 3 months&#xD;
             prior to check-in until completion of the follow-up visit;&#xD;
&#xD;
          -  Male participants must agree not to donate sperm from check-in until 90 days after&#xD;
             completion of the follow-up visit;&#xD;
&#xD;
          -  Females of childbearing potential will agree to use contraception;&#xD;
&#xD;
          -  Able to comprehend the requirements of the study and willing to sign an informed&#xD;
             consent form before any study related procedures are conducted and to abide by the&#xD;
             study restrictions.&#xD;
&#xD;
        For Participants with Normal Hepatic Function-&#xD;
&#xD;
          -  In good health, determined by no clinically significant (CS) findings, as determined&#xD;
             by the investigator, from medical and surgical history, physical examination, 12-lead&#xD;
             ECG, vital signs measurements, and clinical laboratory evaluations (congenital&#xD;
             nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total&#xD;
             and direct bilirubin] is not acceptable) at screening and check-in;&#xD;
&#xD;
          -  Serum electrolytes (sodium, potassium, chloride, bicarbonate, magnesium, and calcium)&#xD;
             within normal limits or if deemed not CS by the investigator judgment in the case of&#xD;
             minor abnormalities;&#xD;
&#xD;
          -  Matched to participants with moderate hepatic impairment in sex, age (±10 years), and&#xD;
             BMI (±20%).&#xD;
&#xD;
        For Participants with Moderate Hepatic Impairment-&#xD;
&#xD;
          -  Diagnosis of chronic (≥3 months prior to screening) and stable hepatic insufficiency&#xD;
             (no acute episodes of illness or deterioration in hepatic function) as assessed by the&#xD;
             investigator with a C-P classification score of 7 to 9 (moderate hepatic impairment).&#xD;
             Evidence of liver disease should be corroborated by medical history;&#xD;
&#xD;
          -  Have current, or a history of at least 1 physical sign consistent with a clinical&#xD;
             diagnosis of liver cirrhosis;&#xD;
&#xD;
          -  Other than hepatic insufficiency with features of cirrhosis, hepatic impairment&#xD;
             participants are in good health and clinically stable based on:&#xD;
&#xD;
               -  stable hepatic function is defined as no recent [i.e., within the preceding 14&#xD;
                  days] CS change in disease status according to the investigator's clinical&#xD;
                  judgment (e.g., no worsening of clinical signs of hepatic impairment, or no&#xD;
                  worsening of total bilirubin or prothrombin by more than 50%).&#xD;
&#xD;
               -  the investigator's assessment including medical history and surgical history&#xD;
                  review, a defined complete physical examination, 12-lead ECG, vital signs, and&#xD;
                  clinical laboratory evaluations (clinical chemistry [including liver function&#xD;
                  tests], hematology, urinalysis, coagulation tests, thyroid function tests).&#xD;
&#xD;
          -  Abnormal laboratory values (hepatic and nonhepatic) must be clinically acceptable by&#xD;
             the investigator (or designee);&#xD;
&#xD;
          -  Participants who need concomitant medications that are not prohibited during this&#xD;
             study must have a medication regimen considered to be stable by the investigator.&#xD;
             (e.g., no new drugs or significant changes to dosage(s) within 2 weeks [or 5&#xD;
             half-lives, whichever is longer] prior to study drug administration on Day 1; no&#xD;
             changes expected during study conduct). Concomitant medications must be reviewed and&#xD;
             approved by the investigator and Labcorp medical monitor (or designee).&#xD;
&#xD;
          -  Anemia secondary to hepatic disease will be acceptable if hemoglobin is ≥8 grams per&#xD;
             deciliter (g/dL) and anemia symptoms are not CS;&#xD;
&#xD;
          -  Participants must have a platelet count ≥35 × 10^9/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all Participants-&#xD;
&#xD;
          -  Presence or history of any disorder that may prevent the successful completion of the&#xD;
             study;&#xD;
&#xD;
          -  Participant is pregnant or breastfeeding;&#xD;
&#xD;
          -  Significant acute, new-onset illness (e.g., flu, gastroenteritis) within 2 weeks prior&#xD;
             to dosing;&#xD;
&#xD;
          -  Inability to swallow medication;&#xD;
&#xD;
          -  Has a history of relevant drug and/or food allergies (i.e., allergy to study drug or&#xD;
             excipients [microcrystalline cellulose, croscarmellose sodium, sodium stearyl&#xD;
             fumarate, mannitol, magnesium stearate, and the Opadry Blue II film-coat&#xD;
             [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and FD&amp;C Blue #2]);&#xD;
&#xD;
          -  Surgical or medical history that, in the opinion of the investigator, may potentially&#xD;
             interfere with study drug absorption, distribution, metabolism, and/or excretion.&#xD;
             Participants who have undergone abdominal surgery or any other major surgical&#xD;
             procedure within 6 months prior to screening, must not be enrolled; The investigator&#xD;
             should be guided by evidence of any of the following:&#xD;
&#xD;
               1. History of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or&#xD;
                  rectal bleeding within the past 3 months.&#xD;
&#xD;
               2. History of major gastrointestinal tract surgery such as gastrectomy,&#xD;
                  gastroenterostomy, or bowel resection.&#xD;
&#xD;
               3. History of pancreatic injury or pancreatitis in the past 6 months; indications of&#xD;
                  impaired pancreatic function/injury as indicated by CS abnormal lipase or&#xD;
                  amylase.&#xD;
&#xD;
               4. History of urinary obstruction or difficulty in voiding in the past 3 months.&#xD;
&#xD;
          -  History or a presence of any malignancy, with the exception of a malignancy that has&#xD;
             been curatively treated and for which the Participant has displayed no evidence of&#xD;
             disease within 12 months prior to screening. Current or history of hepatic carcinoma,&#xD;
             hepatorenal syndrome, portacaval shunt surgery, or pleural effusion. Malignancy,&#xD;
             including leukemia and lymphoma, within the last 5 years. Participants with localized,&#xD;
             fully-treated carcinoma of the skin may be allowed with investigator (or designee)&#xD;
             approval;&#xD;
&#xD;
          -  Confirmed (e.g., 2 consecutive measurements) systolic blood pressure &gt;150 or &lt;90&#xD;
             millimeters of mercury (mmHg), diastolic blood pressure &gt;100 or &lt;50 mmHg, and pulse&#xD;
             rate &gt;100 or &lt;40 beats per minute (bpm); (Note: Participants with vital signs outside&#xD;
             the above ranges may be eligible if the investigator and Labcorp medical monitor deem&#xD;
             the results are not CS.)&#xD;
&#xD;
          -  Clinically significant cardiac history or presence of ECG findings as determined by&#xD;
             the investigator at screening and check-in, including any of the following:&#xD;
&#xD;
               1. Abnormal sinus rhythm (heart rate [HR] lower than 40 bpm and higher than 100 bpm)&#xD;
&#xD;
               2. Risk factors for torsades de pointes (e.g., heart failure, cardiomyopathy, or&#xD;
                  family history of long QT syndrome)&#xD;
&#xD;
               3. Sick sinus syndrome, second- or third-degree atrioventricular block myocardial&#xD;
                  infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or&#xD;
                  conduction abnormalities.&#xD;
&#xD;
               4. QT interval corrected for HR using Fridericia's formula (QTcF) &gt;450 milliseconds&#xD;
                  (msec) (healthy male participants) or &gt;470 msec (healthy female participants) or&#xD;
                  &gt;480 msec for hepatically impaired participants; in the event a QTcF value is&#xD;
                  outside of the reference range, it will be confirmed by 2 repeat measurements,&#xD;
                  which will then be used to calculate a mean from the original value and the 2&#xD;
                  repeat measurements.&#xD;
&#xD;
               5. QRS interval &gt;110 msec, confirmed by manual over read.&#xD;
&#xD;
               6. PR interval &lt;120 and &gt;220 msec.&#xD;
&#xD;
               7. Repeated or frequent syncope or vasovagal episodes.&#xD;
&#xD;
               8. Hypertension, angina, bradycardia (if assessed as CS by the investigator), or&#xD;
                  severe peripheral arterial circulatory disorders.&#xD;
&#xD;
               9. History of autonomic dysfunction.&#xD;
&#xD;
          -  Has estimated glomerular filtration rate &lt;60 mL/minute/1.73 m^2 using Cockcroft-Gault&#xD;
             equation;&#xD;
&#xD;
          -  Administration of a coronavirus disease 2019 vaccine in the past 14 days prior to&#xD;
             dosing;&#xD;
&#xD;
          -  Has a positive test for severe acute respiratory syndrome coronavirus 2; Note: Testing&#xD;
             will be performed according to site procedures;&#xD;
&#xD;
          -  Has an active infection requiring systemic antimicrobial therapy at any time during&#xD;
             the screening period;&#xD;
&#xD;
          -  Is currently enrolled in or has participated in another clinical study to receive any&#xD;
             investigational or marketed product or placebo within 4 weeks (or 5 half-lives,&#xD;
             whichever is longer) or longer as required by local regulations prior to check-in;&#xD;
&#xD;
          -  History of alcohol abuse within 3 months prior to screening and/or alcohol consumption&#xD;
             of &gt;21 units per week for males and &gt;14 units for females. One unit of alcohol equals&#xD;
             12 ounce [oz] (360 mL) beer, 1 1/2 oz (45 mL) liquor, or 5 oz (150 mL) wine;&#xD;
&#xD;
          -  Positive urine, breath, or blood test for alcohol or positive urine drug screen at&#xD;
             screening and/or check-in;&#xD;
&#xD;
          -  Positive urine cotinine test screening and/or at check-in (smokers will be defined as&#xD;
             any participant who reports current tobacco use and/or who has a positive urine&#xD;
             cotinine test);&#xD;
&#xD;
          -  History or suspicion of active substance use disorder prior to check-in (including,&#xD;
             but not limited to: cannabinoids, amphetamines, methamphetamines,&#xD;
             3,4-methylenedioxy-N-methylamphetamine [ecstasy], opiates, methadone, oxycodone,&#xD;
             phencyclidine, cocaine, cotinine, benzodiazepines, and barbiturates);&#xD;
&#xD;
          -  Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages&#xD;
             within 7 days prior to check-in and not willing to refrain from consumption of these&#xD;
             foods or beverages throughout the study until completion of the follow-up visit;&#xD;
&#xD;
          -  Alcohol consumption, starting 48 hours prior to check-in and continuing until&#xD;
             completion of the follow-up visit;&#xD;
&#xD;
          -  Consumption of caffeine- or xanthine-containing products within 48 hours before&#xD;
             check-in until completion of the follow-up visit;&#xD;
&#xD;
          -  Consumption of vegetables from the mustard green family (e.g., kale, broccoli,&#xD;
             watercress, collard greens, kohlrabi, Brussel sprouts, and mustard greens), or&#xD;
             charbroiled meat for 7 days prior to dosing until completion of the follow-up visit;&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to check-in;&#xD;
&#xD;
          -  Participant has donated (or lost) ≥ 400 mL of red blood cells within 2 months prior to&#xD;
             screening, plasma within 2 weeks prior to screening, or platelets within 6 weeks prior&#xD;
             to screening; Participant has planned donation of any blood products after screening&#xD;
             until 3 months after the follow-up visit;&#xD;
&#xD;
          -  Participants are required to refrain from strenuous exercise from 7 days before&#xD;
             check-in until completion of the follow-up visit and will otherwise maintain their&#xD;
             normal level of physical activity during this time (i.e., will not begin a new&#xD;
             exercise program nor participate in any unusually strenuous physical exertion);&#xD;
&#xD;
          -  Poor peripheral venous access;&#xD;
&#xD;
          -  Participants who, in the opinion of the investigator (or designee), should not&#xD;
             participate in this study;&#xD;
&#xD;
          -  Positive hepatitis B surface antigen or human immunodeficiency virus 1 or 2 test.&#xD;
&#xD;
        For Participants with Normal Hepatic Function-&#xD;
&#xD;
          -  Liver test results (alanine aminotransferase, aspartate aminotransferase, alkaline&#xD;
             phosphatase, albumin, or total bilirubin) above the upper limit of normal and/or&#xD;
             prolonged prothrombin time (results may be repeated once), at screening and check-in,&#xD;
             unless deemed not CS approved by the investigator (or designee);&#xD;
&#xD;
          -  Has a known history or presence of liver disease;&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, or psychiatric disorder (as determined by the&#xD;
             investigator);&#xD;
&#xD;
          -  Uses or intends to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including slow-release medications/products, any&#xD;
             over-the-counter medications or herbal or nutritional supplements with the exception&#xD;
             of vitamins, within 14 days (or 5 half-lives, whichever is longer) prior to check-in&#xD;
             and until completion of the follow-up visit, unless deemed acceptable by the&#xD;
             investigator (or designee);&#xD;
&#xD;
          -  Has used any prescription medications (excluding hormone replacement therapy, oral,&#xD;
             implantable, transdermal, injectable, or intrauterine contraceptives), including&#xD;
             systemic antimicrobial therapies, within 30 days (or 5 half-lives, whichever is&#xD;
             longer) before dosing or during the study (ie, through the follow-up visit);&#xD;
&#xD;
          -  Positive hepatitis C antibody;&#xD;
&#xD;
          -  History of diabetes mellitus.&#xD;
&#xD;
        For Participants with Hepatic Impairment-&#xD;
&#xD;
          -  Participants receiving strong and moderate cytochrome P450 (CYP) 3A inhibitors that&#xD;
             have not been stopped for ≥5 days or a time frame equivalent to 5 half-lives&#xD;
             (whichever is longer), or strong and moderate CYP3A inducers that have not been&#xD;
             stopped for ≥4 weeks or a time frame equivalent to 5 half-lives (whichever is longer),&#xD;
             before administration of the study drug;&#xD;
&#xD;
          -  Participants with Grade 2 or higher encephalopathy, as defined by the grading scale in&#xD;
             the Food and Drug Administration (FDA) guidance on PK studies in participants;&#xD;
&#xD;
          -  Participant has a portal systemic shunt;&#xD;
&#xD;
          -  Participant demonstrates evidence of hepatorenal syndrome;&#xD;
&#xD;
          -  Participant has required treatment for gastrointestinal bleeding within the 3 months&#xD;
             prior to check-in (Participants demonstrating banding procedure within 1 month prior&#xD;
             to check-in may be included at the discretion of the investigator [or designee]);&#xD;
&#xD;
          -  Participant has required new medication or a change in dose for hepatic encephalopathy&#xD;
             within 3 months prior to check-in, unless approved by the investigator (or designee);&#xD;
&#xD;
          -  Participants who require paracentesis within 3 months prior to check-in or planned&#xD;
             during the study;&#xD;
&#xD;
          -  Clinical evidence of moderate to severe ascites;&#xD;
&#xD;
          -  Any evidence of progressive liver disease (between screening and check-in) as&#xD;
             indicated by liver transaminases, alkaline phosphatase, or gamma-glutamyl transferase,&#xD;
             or a ≥50% worsening of serum bilirubin or prothrombin time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Chair</role>
    <affiliation>Agios Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Affairs</last_name>
    <phone>833-228-8474</phone>
    <email>medinfo@agios.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Center (OCRC)</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami (CPMI)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center (OCRC)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>April 21, 2023</last_update_submitted>
  <last_update_submitted_qc>April 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AG-348</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Hepatic Impairment</keyword>
  <keyword>pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

